Evidence map›Paper›PMID 40772298›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2025

Plasma

Ruifang Li-Gao, Marco R Bladergroen, Frits R Rosendaal, Manfred Wuhrer, Astrid van Hylckama Vlieg

Abstract readMulticenter Study
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruifang Li-GaoDepartment of Clinical Epidemiology (R.L.-G., F.R.R., A.v.H.V.), Leiden University Medical Center, the Netherlands.ORCID 0000-0003-0650-1351
Marco R BladergroenCenter for Proteomics and Metabolomics (M.R.B., M.W.), Leiden University Medical Center, the Netherlands.ORCID 0000-0003-4434-4799
Frits R RosendaalDepartment of Clinical Epidemiology (R.L.-G., F.R.R., A.v.H.V.), Leiden University Medical Center, the Netherlands.ORCID 0000-0003-2558-7496
Manfred Wuhrer *Center for Proteomics and Metabolomics (M.R.B., M.W.), Leiden University Medical Center, the Netherlands.ORCID 0000-0002-0814-4995
Astrid van Hylckama Vlieg *Department of Clinical Epidemiology (R.L.-G., F.R.R., A.v.H.V.), Leiden University Medical Center, the Netherlands.ORCID 0000-0001-7386-1168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoagulation factors play important roles in the pathophysiology of venous thromboembolism (VTE), and most of them are glycoproteins, that is, proteins containing glycans attached. Although the connection between glycosylation and coagulation factors seems obvious, the association between glycosylation and VTE risk remains unexplored. We aimed to elucidate the association between

methodsThe total plasma

resultsIn the analysis, 466 idiopathic VTE cases and 454 controls were included. We found that fucosylation of complex-type glycans and the presence of more antennae in glycan structures were associated with an increased risk of VTE. Conversely, monoantennary and diantennary complex-type glycans, as well as oligomannose-type glycans, were associated with a reduced risk of VTE. The associations between glycan features and VTE risk were partially supported by their relationships with procoagulant factors.

conclusionsWe demonstrated the relevance of plasma

Indexed as

PolysaccharidesVenous ThromboembolismAdultAgedBiomarkersBlood CoagulationCase-Control StudiesFemaleGlycomicsGlycosylationHumansMaleMiddle AgedRisk AssessmentRisk FactorsBiomarkersPolysaccharidesblood coagulation factorsglycoproteinsglycosylationrisk factorsvenous thromboembolism

Identifiers

PMID40772298
PMCPMC12379778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.